Celularity (NASDAQ:CELU) Stock Price Down 3% - Should You Sell?

Celularity, Inc. (NASDAQ:CELU - Get Free Report) shares traded down 3% on Tuesday . The company traded as low as $3.14 and last traded at $3.19. 134,420 shares were traded during mid-day trading, a decline of 77% from the average session volume of 580,949 shares. The stock had previously closed at $3.29.

Wall Street Analyst Weigh In

Separately, Wall Street Zen lowered Celularity from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd.

Celularity Stock Down 4.9%

The stock's fifty day moving average is $2.28 and its two-hundred day moving average is $1.96. The company has a market capitalization of $74.72 million, a PE ratio of -1.18 and a beta of 0.74. The company has a current ratio of 0.38, a quick ratio of 0.28 and a debt-to-equity ratio of 4.07.

Celularity (NASDAQ:CELU - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($1.50) by $0.91. The firm had revenue of $18.13 million during the quarter, compared to the consensus estimate of $5.20 million. Celularity had a negative net margin of 106.77% and a negative return on equity of 271.88%.

Institutional Investors Weigh In On Celularity

Hedge funds and other institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC bought a new position in shares of Celularity in the first quarter worth approximately $34,000. Biltmore Family Office LLC bought a new stake in shares of Celularity in the 4th quarter worth about $73,000. Two Sigma Investments LP purchased a new position in shares of Celularity during the 4th quarter worth about $93,000. Finally, Valmark Advisers Inc. purchased a new stake in Celularity in the second quarter worth $98,000. Institutional investors own 19.02% of the company's stock.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.